Market
1 million doses of self-amplifying RNA COVID-19 vaccine administered in EU by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Reports from European public health agencies or EU health statistics
Story
EU to Approve U.S. Self-Amplifying RNA COVID-19 Vaccine Following Japan's Approval of ARCT-154 Self-Replicating mRNA
Dec 17, 2024, 02:23 PM
The European Union is set to approve a new self-amplifying RNA-based COVID-19 vaccine developed by a U.S. company. This follows Japan's recent approval of a similar self-replicating mRNA vaccine, ARCT-154, which allows the mRNA to replicate within cells. The advancements in mRNA technology, including the use of lipid nanoparticles (LNPs), are aimed at enhancing vaccine efficacy and targeting specific diseases. Researchers have also made progress in developing modified LNPs capable of crossing the blood-brain barrier, potentially enabling targeted therapies for brain and inflammatory diseases.
View original story
Similar markets
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10 to 50 million • 25%
More than 100 million • 25%
Less than 10 million • 25%
50 to 100 million • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
50,001 to 100,000 • 25%
Less than 10,000 • 25%
More than 100,000 • 25%
10,000 to 50,000 • 25%
100,000 to 500,000 doses • 25%
More than 1,000,000 doses • 25%
500,001 to 1,000,000 doses • 25%
Less than 100,000 doses • 25%
More than 100,000 • 25%
50,001 to 100,000 • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
5 to 10 million • 25%
Less than 1 million • 25%
1 to 5 million • 25%
More than 10 million • 25%
100,000 to 199,999 doses • 25%
300,000 or more doses • 25%
Less than 100,000 doses • 25%
200,000 to 299,999 doses • 25%
10 to 50 million doses • 25%
More than 100 million doses • 25%
50 to 100 million doses • 25%
Less than 10 million doses • 25%
Yes • 50%
No • 50%
70% to 90% • 25%
Less than 50% • 25%
50% to 70% • 25%
More than 90% • 25%